Research and clinical applications of cancer genome sequencing

Current Opinion in Obstetrics & Gynecology
Chee S KuDimitrios H Roukos


To highlight the recent advances in cancer genome research and its clinical applications made possible by next-generation sequencing (NGS), with particular emphasis on gynecological and breast cancers is the purpose of the review. Through advances in NGS technologies, whole-exome sequencing and whole-genome sequencing (WGS) have been performed on various cancers, identifying in the process numerous recurrent mutations and highly mutated genes. These cancers include uterine serous carcinomas, high-grade serous ovarian adenocarcinomas and breast cancer. In contrast to identifying somatic mutations in sporadic cancers, a far smaller number of studies using NGS have been conducted to identify new causal mutations or genes for hereditary cancer syndromes. In addition to research discovery, diagnostic applications of NGS have also become increasingly evident. Thus, WGS has been applied in a diagnostic context to identify a complex chromosomal rearrangement in a patient with acute myeloid leukemia of unclear subtype. Similarly, the targeted sequencing of panels of known cancer genes using NGS has demonstrated its robustness in the context of identifying known pathological mutations. The research and clinical applications of cancer gen...Continue Reading


Aug 31, 2013·Oncology Nursing Forum·Suzanne M Mahon
May 2, 2018·Personalized Medicine·Leland E Hull, Jason L Vassy
Oct 19, 2017·Current Protocols in Human Genetics·Elizabeth A Worthey
Aug 8, 2013·Environmental and Molecular Mutagenesis·Giuseppe MatulloSimonetta Guarrera
Apr 15, 2015·Current Opinion in Endocrinology, Diabetes, and Obesity·Rodrigo A Toledo, Patricia L M Dahia


Apr 11, 2009·Nature·Michael R StrattonP Andrew Futreal
May 23, 2009·Nature Reviews. Cancer·Robert C BastGordon B Mills
Dec 10, 2009·Nature Reviews. Genetics·Michael L Metzker
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Tom WalshMary-Claire King
Sep 18, 2010·Nature Reviews. Genetics·Matthew MeyersonGad Getz
Mar 26, 2011·Science·Michael R Stratton
Apr 21, 2011·JAMA : the Journal of the American Medical Association·Daniel C LinkElaine R Mardis
Apr 21, 2011·JAMA : the Journal of the American Medical Association·John S WelchRichard K Wilson
Jun 7, 2011·Annual Review of Genomics and Human Genetics·Kit Man WongJohn D McPherson
Jun 21, 2011·Nature Genetics·Iñaki Comino-MéndezAlberto Cascón
Jul 2, 2011·Nature·Cancer Genome Atlas Research Network
Oct 19, 2011·Proceedings of the National Academy of Sciences of the United States of America·Tom WalshElizabeth M Swisher
Dec 3, 2011·Science Translational Medicine·Sameek RoychowdhuryArul M Chinnaiyan
Mar 1, 2012·Expert Review of Molecular Diagnostics·Chee-Seng KuRichie Soong
Apr 24, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Chee-Seng KuBarry Iacopetta
Apr 24, 2012·Nature Biotechnology·Nicholas J LomanMark J Pallen
Jun 5, 2012·The Journal of Molecular Diagnostics : JMD·Colin C PritchardTom Walsh
Jun 23, 2012·Nature·Matthew J EllisElaine R Mardis
Jun 23, 2012·Nature·Philip J StephensMichael R Stratton
Jun 23, 2012·Nature·Shantanu BanerjiMatthew Meyerson
Aug 28, 2012·Journal of the National Cancer Institute·Elisabetta KuhnIe-Ming Shih

Related Concepts

Somatic Mutation
Acute Myeloid Leukemia Pathway
Massively-Parallel Sequencing
Genital Neoplasms, Female
Sequence Determinations, DNA
Neoplastic Syndromes, Hereditary

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Current Opinion in Oncology
Christine DesmedtPeter J Campbell
Current Opinion in Pediatrics
David Bick, David Dimmock
The Journal of Surgical Research
Christos KatsiosDimitrios H Roukos
The Journal of Clinical Endocrinology and Metabolism
Marina N NikiforovaYuri E Nikiforov
© 2020 Meta ULC. All rights reserved